Sevelamer hydrochloride versus aluminum hydroxide: Effect on serum phosphorus and lipids in CAPD patients

Peritoneal Dialysis International

Volumn 26, Issue 3, 2006, Pages 320-327

  Katopodis, Konstantinos P ^a   Andrikos, Emilios K ^b   Gouva, Chariklia D ^a   Bairaktari, Eleni T ^a   Nikolopoulos, Petros M ^a   Takouli, Lamprini K ^a   Tzallas, Christos S ^a   Elisaf, Moses S ^a   Pappas, Michael V ^b   Siamopoulos, Kostas C ^a,c  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Lipids; Phosphorus binders; Sevelamer hydrochloride

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; CALCIUM; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; HYPERPHOSPHATEMIA; LIPID BLOOD LEVEL; MALE; NAUSEA; OPEN STUDY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 33748427501     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080602600308     Document Type: Article

References (41)

1. Llach F. Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences. Kidney Int Suppl 1999; 73:S31-7.
2. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29:66-71.
3. Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW. Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 1982; 2:849-61.
4. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53:1399-404.
5. Zucchelli P, Santoro A. Inorganic phosphate removal during different dialytic procedures. Int J Artif Organs 1987; 10:173-8.
6. Hou SH, Zhao J, Ellman CF, HU J, Griffin Z, Spiegel D, et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 1991; 18:217-24.
7. Hercz G, Coburn JW. Prevention of phosphate retention and hyperphosphatemia in uremia. Kidney Int Suppl 1987; 22:S215-20.
8. Boyce BF, Fell GS, Elder HY, Junor BJ, Elliot HL, Beastall G, et al. Hypercalcaemic osteomalacia due to aluminium toxicity. Lancet 1982; 2:1009-13.
9. Alfrey AC, LeGendre GR, Kaehney WD. The dialysis encephalopathy syndrome: possible aluminum intoxication. N Engl J Med 1976; 294:184-8.
10. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315:157-61.
11. Emmett M, Sirmon MD, Kirkpartick WG, Nolan CR, Schmitt GW, Cleveland MV. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991; 17:544-50.
12. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard D. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321:274-9.
13. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel®, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997; 12:1640-4
14. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33:694-701.
15. Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 1998; 50:381-6.
16. Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, et al. Effect of RenaGel®, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998; 13:2303-10.
17. Slatopolsky EA, Burke SK, Dillon MA, and the RenaGel® Study Group. RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55:299-307.
18. Sadek T, Mazouz H, Bahloul H, Oprisiu R, El Esper N, El Esper I, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 2003; 18:582-9.
19. Mahdavi H, Kuizon BD, Gales B, Wang HJ, Elashoff RM, Salusky IB. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol 2003; 18:1260-4.
20. NKF. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3):S1-202.
21. Janssen MJA, van der Kuy A, ter Wee PM, van Boven WPL. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996; 45:111-19.
22. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vivo in vitro study. J Clin Invest 1989; 83:66-73.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:495-502.
24. Winney RJ, Cowie JF, Robson JS. Role of plasma aluminum in the detection and prevention of aluminum toxicity. Kidney Int Suppl 1986; 18:S91-5.
25. Shany S, Rapoport J, Goligorsky M, Yankowitz N, Zuili I, Chaimovitz C. Losses of 1,25- and 24,25-dihydroxycholecalciferol in the peritoneal fluid of patients treated with continuous ambulatory peritoneal dialysis.Nephron 1984; 36:111-13.
26. Fournier A, Barsoum J, Fickl R, Oprisiu R, El Esper N, Moriniere P. Sevelamer, CaxP product and vitamin D. Nephrol Dial Transplant 2001; 16:429-30.
27. BaLasa RW, Murray RL, Kondelis NP, Bischel MD. Phosphate binding properties and electrolyte content of aluminum hydroxide antacids. Nephron 1987; 45:16-21.
28. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI. Effect of Renagel, a non-absorbable, cross link polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant 1997; 12:961-4.
29. Swearingen RA, Chen X, Petersen JS, Riley KS, Wang D, Zhorov E. Determination of the binding parameter constant of Renagel capsules and tables utilizing the Langmuir approximation at various pH by ion chromatography. J Pharm Biomed Anal 2002; 29:195-201.
30. Baigent C, Wheeler DC. Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure? Nephrol Dial Transplant 2000; 15:1118-19.
31. Walter R, Mischak H, Haller H. Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESRD patients. Nephrol Dial Transplant 2002; 17:24-9.
32. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149:820-5.
33. Cousar GD, Gadacz TR. Comparison of antacids on the binding of bile salts. Arch Surg 1984; 119:1018-20.
34. Kivilaakso E. Antacids and bile salts. Scand J Gastroenterol 1982; 75(Suppl):16-19.
35. Sperber AD, Henkin Y, Zuili I, Bearman JE, Shany S. The hypocholesterolemic effect of an antacid containing aluminum hydroxide. Am J Med 1991; 91:597-604.
36. Elisaf MS, Bairaktari ET, Tzallas CS, Siamopoulos KC. The hypolipidaemic effectiveness of antacids containing aluminium atone and in combination with small doses of pravastatin. J Drug Dev Clin Pract 1996; 8:101-7.
37. Wrong OM, Herland CE. Sevelamer induced acidosis. Kidney Int 2005; 67:776-7.
38. Paz Marco M, Muray S, Betriu A, Craver L, Belart M, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002; 92: 499-500.
39. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int 2000; 57:1776-7.
40. Borras M, Marco MP, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit Dial Int 2002; 22:737-8.
41. Kasimatis E, Maksich D, Jassal V, Bargman JM, Oreopoulos DG. Predictive factors of low HCO3 levels in peritoneal dialysis patients. Clin Nephrol 2005; 63:290-6.